查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853486

口腔給藥系統市場按產品類型、藥物類別、應用、最終用戶和分銷管道分類－2025-2032年全球預測

Buccal Drug Delivery Systems Market by Product Type, Drug Class, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口腔給藥系統市場規模將成長 51 億美元，複合年成長率為 9.68%。

主要市場統計數據
基準年 2024 24.3億美元
預計年份：2025年 26.7億美元
預測年份：2032年 51億美元
複合年成長率 (%) 9.68%

本文簡要說明了口腔給藥系統的現狀，重點介紹了影響該領域的技術、臨床和商業性促進因素。

口腔給藥系統已從最初的小眾製劑發展成為靶向、快速且對患者友好的全身和局部治療的核心方式。聚合物科學、黏膜黏附化學和器械工程的進步拓展了研發人員可用的劑型，為疼痛管理、荷爾蒙療法、心血管治療等領域提供了新的治療機會。臨床醫生和患者都重視生物有效性原料藥利用度以及繞過肝臟初始代謝（適用於那些不宜經口腔粘膜最佳遞送的藥物）等優點。

這些因素包括：更先進的輔料套件包，可實現精確的藥物釋放動力學；新型給藥平台的監管核准取決於可靠的安全性數據；以及不斷壯大的合約開發商和器械專家生態系統，他們能夠將配方轉化為可生產的產品。同時，患者的期望也轉向了更方便、易於給藥且能與院外醫療管道整合的治療方法。這些趨勢正在加速轉化研究，增加從臨床前試驗進入臨床評估階段的項目數量，同時也加劇了配方方法和供應商之間的競爭。

本執行摘要概述了當前形勢，指出了變革性轉變，評估了不斷變化的貿易政策壓力帶來的影響，並就市場細分、區域動態、企業行為和戰略舉措建議提供了切實可行的見解。其目的是為決策者提供結構化、以證據為依據的視角，以支持其優先考慮發展投資、供應鏈韌性規劃和相關人員參與，從而明確商業化路徑。

材料進步、監管適應症和以患者為中心的設計如何從根本上改變口腔藥物開發和商業化的軌跡

口腔給藥領域正經歷顯著的變革，這主要得益於材料創新、法規的不斷改進以及病患照護模式的轉變。材料科學的最新突破催生了多功能聚合物的研發，這些聚合物兼具強粘附性、控制釋放和舒適性，從而能夠製備更薄的薄膜、更柔韌的貼劑以及具有可預測藥物動力學特徵的噴霧劑。同時，裝置的小型化和驅動設計的改進減少了操作誤差，提高了給藥的一致性，從而改善了患者的用藥依從性，並使其在門診病人的應用範圍更廣。

法律規範正在調整以適應平台技術和組合藥物，鼓勵申辦方更早投資於監管策略和人因工程，從而降低臨床試驗計畫的風險。對真實世界證據和上市後監測的期望也在發生變化，要求將使用數據和安全性監測納入產品開發計劃。與監管變化同步，商業模式也不斷演變。專業製劑商、契約製造和臨床服務供應商之間的合作正在縮短研發週期，並降低小型創新企業的技術准入門檻。

以病人為中心的設計原則和數位化醫療的融合正變得日益重要。注重給藥便利性、最大限度減少口味影響和便於隱蔽使用的配方正受到配方師和患者的青睞。與遠端醫療、依從性追蹤技術和數位指導工具的整合，進一步提升了口腔給藥系統在以便捷性和持續給藥為核心的照護路徑中的價值。這些轉變共同拓展了研發者的策略選擇，同時也提高了產品生命週期內證據和可用性的標準。

評估2025年美國關稅變化對供應鏈製造經濟和戰略採購決策的多面向影響

美國在2025年實施或提高關稅將對口腔給藥領域產生多方面的影響，包括採購、生產成本和策略夥伴的選擇。關稅壓力通常會增加進口原料和特殊成分的到岸成本，迫使研發商和契約製造生產商重新評估其供應商組合。對於高價值輔料、黏合層壓材料和精密製造零件等國際採購產品，提高進口關稅可能會對其利潤率造成壓力，並促使其尋找替代供應商或將上游生產轉移到關稅優惠的地區。

為因應關稅導致的成本上升，企業通常會加快供應鏈多元化和雙源籌資策略，以減少對過度進口管道的依賴。這往往會導致企業增加對近岸外包和區域製造的投資，因為企業希望在地理上更緊密地協調產品開發、監管申報和商業性分銷管道。此類轉變可以縮短前置作業時間並控制質量，但可能需要前期投資和更長的檢驗期。

關稅也會透過改變不同市場的相對成本結構來影響競爭動態。雖然一些贊助商可能會承受短期成本上漲，但其他贊助商可能會優先考慮成本控制，例如最佳化配方以去除昂貴的成分，或改進包裝和物流以最大限度地降低課稅價格。最後，貿易政策的變化通常會導致產業和監管機構更積極參與其中，促使他們要求澄清組合藥物的關稅分類，並就符合免稅或優惠待遇條件的投入品尋求海關指導。總體而言，2025 年關稅的影響可能會促進口腔給藥生態系統內供應鏈韌性措施的加強、策略性回流考量以及採購流程的日益精細化。

將產品劑型、治療層級、護理環境和分銷管道與策略發展重點聯繫起來，以實現全面的細分整合。

深入的市場區隔分析揭示了產品設計選擇、治療標靶和商業化管道如何相互交織，共同塑造了專案優先事項。依產品類型分類，市場可分為薄膜、凝膠、貼片、噴霧劑和片劑。薄膜可依其所用材料進一步細分為纖維素衍生物、天然聚合物和合成聚合物。纖維素衍生物通常採用羥丙基甲基纖維素和微晶纖維素來調節溶解度和黏附性。凝膠分為水凝膠和有機凝膠，二者在水合性和藥物釋放特性上有差異。貼片分為黏性貼劑和基質貼片，體現了應用舒適性和生產複雜性之間的權衡。片劑又可進一步分為咀嚼片、錠劑和黏膜黏附片，從而可以更好地控制黏膜接觸和偏好。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 用於提高口服藥物生物有效性度的黏膜黏附奈米顆粒製劑的進展
  • 利用3D列印技術客製化口服薄膜劑型，實現個人化治療
  • 尋找滲透促進劑以最佳化藥物經由口腔黏膜的吸收
  • 開發用於慢性疼痛管理治療的緩釋性口腔黏附凝膠
  • 利用口腔貼片中的無線感測器進行即時病患遵從性監測
  • 透過引入環狀胜肽載體，提高了口腔內疫苗遞送的穩定性。
  • 影響新型口服藥物遞送系統核准的監管挑戰和協調工作
  • 利用口腔遞送胜肽類和小分子藥物治療慢性疾病

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的口腔給藥系統市場

  • 電影
    • 纖維素衍生物
      • 羥丙基甲基纖維素
      • 微晶纖維素
    • 天然聚合物
    • 合成聚合物
  • 凝膠
    • 水凝膠
    • 有機凝膠
  • 修補
    • 黏性貼片
    • 矩陣補丁
  • 噴
    • 多驅動
    • 單次驅動
  • 藥片
    • 咀嚼片
    • 錠劑
    • 黏膜黏附片

9. 按藥物類別分類的口腔給藥系統市場

  • 止痛藥
    • Buprenornhine
    • Fentanyl
  • 心血管系統
    • 硝酸甘油
  • 中樞神經系統
  • 荷爾蒙
    • 雌二醇
    • 睪固酮

第10章 按應用分類的口腔給藥系統市場

  • 心血管治療
  • 荷爾蒙療法
  • 疼痛管理
  • 精神科護理

第11章 依最終使用者分類的口腔給藥系統市場

  • 診所
  • 居家醫療
  • 醫院

第12章 按分銷管道分類的口腔給藥系統市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

13. 按地區分類的口腔給藥系統市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口腔給藥系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國口腔給藥系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • Novartis AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Bausch Health Companies Inc.
    • BioDelivery Sciences International, Inc.
    • Roche Holding AG
Product Code: MRR-3A2E844FF422

The Buccal Drug Delivery Systems Market is projected to grow by USD 5.10 billion at a CAGR of 9.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.43 billion
Estimated Year [2025] USD 2.67 billion
Forecast Year [2032] USD 5.10 billion
CAGR (%) 9.68%

A concise orientation to the current state of buccal drug delivery systems capturing technological, clinical, and commercial drivers reshaping the field

Buccal drug delivery systems have evolved from niche formulations to a core modality for targeted, rapid and patient-friendly systemic and local therapies. Advances in polymer science, mucoadhesive chemistries and device engineering have expanded the palette of dosage forms available to developers, enabling new therapeutic opportunities across pain management, hormonal therapies and cardiovascular care. Clinicians and patients alike appreciate buccal routes for their noninvasive administration, improved bioavailability for suitable APIs, and the ability to bypass first-pass hepatic metabolism for drugs where oral delivery is suboptimal.

The clinical and commercial interest in buccal delivery is being shaped by converging forces: more sophisticated excipient toolkits that allow precise release kinetics, regulatory acceptance of novel delivery platforms contingent on robust safety data, and a growing ecosystem of contract developers and device specialists able to translate formulations into manufacturable products. Concurrently, patient expectations are shifting toward discreet, easy-to-administer therapies that integrate with care pathways outside the hospital. These dynamics are accelerating translational activity and increasing the number of programs progressing from preclinical demonstration to clinical evaluation, while also intensifying competition among formulation approaches and supplier partnerships.

This executive summary frames the current state of the landscape, highlights transformational shifts, assesses the implications of evolving trade policy pressures, and provides pragmatic insights on segmentation, regional dynamics, corporate behavior and recommended strategic moves. The objective is to equip decision-makers with a structured, evidence-based view that supports prioritization of development investments, supply chain resiliency planning and engagement with regulatory stakeholders to clear pathways for commercialization.

How material advances regulatory adaptation and patient-centric design are fundamentally changing development and commercial pathways for buccal therapies

The landscape for buccal drug delivery is undergoing transformative shifts driven by material innovation, regulatory evolution, and changing patient care models. Recent material science breakthroughs have led to multifunctional polymers that combine strong mucoadhesion with controlled release and patient comfort, enabling thinner films, more flexible patches and spray formulations that achieve predictable pharmacokinetic profiles. At the same time, device miniaturization and actuation design have reduced user error and increased dosing consistency, which enhances adherence and supports broader outpatient use.

Regulatory frameworks are adapting to accommodate platform technologies and combination products, prompting sponsors to invest earlier in regulatory strategy and human factors engineering to de-risk clinical programs. Real-world evidence and post-market surveillance expectations are also shifting, requiring integration of usage data and safety monitoring into product development plans. Parallel to regulatory change, commercial models are evolving: partnerships between specialty formulation houses, contract manufacturers and clinical service providers are shortening development timelines and lowering technical barriers to entry for smaller innovators.

Patient-centric design principles and digital health linkages are increasingly influential. Formulations that prioritize ease of administration, minimal taste impact and discreet handling are gaining traction among prescribers and patients. Integration with telemedicine, adherence-tracking technologies and digital instructional aids further amplifies the perceived value of buccal delivery systems in care pathways where convenience and consistent dosing are paramount. Together, these shifts are expanding the strategic options for developers while raising the bar for evidence and usability across product lifecycles.

Evaluating the multifaceted consequences of United States tariff changes in 2025 on supply chains manufacturing economics and strategic sourcing decisions

The imposition or increase of tariffs by the United States in 2025 would have a multi-dimensional effect on the buccal drug delivery sector, influencing sourcing, manufacturing economics and strategic partner selection. Tariff pressure typically increases the landed cost of imported raw materials and specialized components, which forces developers and contract manufacturers to reassess supplier portfolios. For high-value excipients, adhesive laminates, and precision manufacturing components that are sourced internationally, increased import duties would create margin pressure and could incentivize qualification of alternate suppliers or relocation of upstream production to tariff-favored jurisdictions.

In response to tariff-driven cost increases, companies often accelerate supply chain diversification and dual-sourcing strategies to mitigate exposure to import-heavy routes. This tends to elevate nearshoring and regional manufacturing investment as sponsors seek closer geographic alignment between development, regulatory submission, and commercial distribution channels. Such shifts can improve lead times and control over quality but may require upfront capital and extended validation timelines.

Tariffs also influence competitive dynamics by altering relative cost structures across markets. Some sponsors may absorb short-term cost increases, while others could prioritize cost-containment via formulation optimization to reduce expensive components, or by altering packaging and logistics to minimize dutiable value. Finally, trade policy shifts typically heighten engagement between industry and regulators, prompting requests for clarifications on tariff classifications for combination products and for customs guidance on inputs that are eligible for exemptions or preferential treatment. Overall, tariff effects in 2025 would act as a catalyst for supply chain resilience measures, strategic reshoring considerations and intensified procurement sophistication within the buccal delivery ecosystem.

A comprehensive segmentation synthesis linking product formulations therapeutic classes care settings and distribution channels to strategic development priorities

Insightful segmentation analysis underscores how product design choices, therapeutic targets and commercialization pathways intersect to shape program priorities. Based on product type, the field encompasses films, gels, patches, sprays, and tablets, where films are further differentiated by cellulose derivatives, natural polymers, and synthetic polymers; within cellulose derivatives, formulations commonly leverage hydroxypropyl methylcellulose and microcrystalline cellulose to tune dissolution and adhesion. Gels bifurcate into hydrogels and organogels that offer distinct hydration and drug-release profiles, while patches are manufactured as either adhesive patches or matrix patches reflecting trade-offs between application comfort and manufacturing complexity. Spray formats are categorized by multi-actuation and single-actuation systems, each supporting different dosing strategies, and tablet options span chewable tablets, lozenges, and mucoadhesive tablets that deliver controlled mucosal contact and palatability.

Based on drug class, developers are targeting analgesics, cardiovascular agents, central nervous system therapies, and hormones. Analgesic programs commonly explore buprenorphine and fentanyl derivatives for rapid-onset pain management and opioid-dependence therapies, while cardiovascular efforts frequently evaluate nitroglycerin for acute angina relief via transmucosal absorption. Hormone-focused delivery studies emphasize estradiol and testosterone for hormone replacement strategies that benefit from mucosal uptake and dose precision.

Based on application, product development is organized around cardiovascular treatment, hormone therapy, pain management, and psychiatry, each application presenting unique pharmacokinetic, safety and usability constraints that inform formulation choice and device architecture. Based on end user, the market must account for clinics, home care, and hospitals, with each setting imposing specific requirements for administration training, packaging robustness and storage. Based on distribution channel, commercialization strategies are tailored to hospital pharmacy, online pharmacy, and retail pharmacy channels, which determine labeling, patient education needs and fulfillment logistics. Together, these segmentation dimensions provide a matrix to prioritize R&D investments and align clinical evidence generation with intended use environments.

Regional dynamics and regulatory variations across the Americas Europe Middle East & Africa and Asia-Pacific that shape market entry and manufacturing strategies

Regional dynamics are central to strategic planning as regulatory frameworks, manufacturing ecosystems and payer behaviors vary significantly across geographies. In the Americas, regulatory emphasis on robust clinical evidence and well-defined labeling for transmucosal products coexists with a mature contract manufacturing sector and an appetite for outpatient-friendly formulations. This region favors rapid deployment of products that demonstrate clear benefits in adherence or pharmacokinetics, and it supports innovative reimbursement pathways for therapies that reduce acute care utilization.

In Europe, Middle East & Africa, regulatory heterogeneity necessitates targeted pathways for approval and post-market surveillance. Manufacturers must navigate regional differences in pharmacovigilance requirements and device classification rules, while leveraging strong CDMO networks in parts of Western Europe for pilot-scale and commercial manufacturing. Market access in this region is increasingly driven by health technology assessment mechanisms and cost-effectiveness arguments, particularly for therapies that displace more resource-intensive interventions.

In Asia-Pacific, dynamic growth in clinical research capacity and investments in local manufacturing create opportunities for scale and cost-effective production. Regulatory authorities in several markets are modernizing frameworks for combination products, and the rapidly expanding middle-class patient population is driving demand for convenient, outpatient-friendly drug delivery options. Across all regions, regionalization of supply chains and regulatory intelligence functions is becoming a best practice to reduce time-to-market and to optimize commercial rollout sequencing based on payer receptivity and clinical adoption patterns.

How specialist innovators strategic partnerships and contract manufacturers are shaping competitive advantage and value creation in buccal delivery

Corporate behavior within the buccal delivery ecosystem is characterized by a blend of specialist innovators, strategic partnerships, and an active outsourcing market for development and manufacturing. Companies focused on novel excipients and mucoadhesive chemistries invest in proprietary platforms that can be licensed to originators or biotechs seeking differentiated release profiles and tactile properties. Contract development and manufacturing organizations play a pivotal role in translating lab-scale prototypes into commercial processes, often providing end-to-end services that reduce capital requirements for product sponsors.

Strategic collaborations between formulation houses, device engineers and clinical services firms are increasingly prevalent, accelerating clinical development timelines and facilitating the integration of human factors and usability testing early in the design cycle. Corporate strategies also emphasize intellectual property protection around both formulation and delivery systems, balanced with selective licensing to expand geographic reach or therapeutic scope. In parallel, smaller specialist firms tend to focus on high-value niches such as opioid substitution therapies or hormone replacement products where buccal administration provides distinct clinical advantages.

Investors and corporate development teams are prioritizing assets that demonstrate clear differentiation in user experience, manufacturability and regulatory readiness. There is also growing attention to sustainability in packaging and supply chain transparency, as procurement teams place higher value on suppliers that can demonstrate environmental and social governance practices. Together, these trends highlight a competitive environment where technical excellence, regulatory foresight and strategic partnering determine which companies can scale and sustain commercial success.

Practical strategic actions for developers manufacturers and investors to de-risk programs accelerate timelines and maximize commercial uptake in buccal therapies

To navigate the opportunities and risks in buccal drug delivery, industry leaders should adopt a multi-pronged strategy that aligns technical, regulatory and commercial priorities. First, prioritize cross-functional regulatory planning early in development to define the combination product pathway, human factors requirements and post-market surveillance obligations; this reduces downstream surprises and optimizes trial design. In parallel, invest in formulation robustness and manufacturability assessments to ensure that chosen excipients and device interfaces scale reliably and meet quality-by-design expectations.

Second, build resilient supply chains through supplier qualification, dual-sourcing and regional manufacturing options to mitigate the impact of trade policy shifts and logistics disruptions. Engaging contract manufacturing partners with proven experience in mucoadhesive systems can compress development timelines while preserving quality control. Third, embed patient-centered design criteria in product development, including palatability, ease of administration and adherence support, and validate these attributes through early human factors testing and real-world pilot studies to inform labeling and training materials.

Fourth, pursue strategic collaborations and licensing arrangements to access complementary capabilities such as advanced polymers or device actuation technology rather than attempting to internalize all competencies. Finally, incorporate sustainability and traceability into procurement and packaging decisions to meet growing payer and institutional buyer expectations and to reduce long-term operational risk. These actions together create a pragmatic roadmap to de-risk development, accelerate market entry and enhance commercial uptake.

A robust mixed-methods research approach combining primary expert interviews and secondary technical regulatory review to ensure actionable and validated insights

This analysis synthesizes primary qualitative engagement with clinical experts formulation scientists regulatory specialists and supply chain managers, combined with structured secondary research into published regulatory guidance technical literature and company disclosures. Primary inputs included targeted interviews to surface real-world operational constraints and human factors considerations that are often absent from public filings, while secondary sources provided context on material science trends and regulatory precedent for combination products.

The research methodology prioritized triangulation across data streams to validate conclusions. Technical claims regarding polymer behavior and device performance were cross-checked with peer-reviewed literature and vendor technical dossiers. Regulatory pathway observations were referenced to publicly available guidance documents and precedent submissions, and policy-related inferences about trade impacts were grounded in documented tariff mechanisms and historical market responses. Where appropriate, anonymized practitioner perspectives were used to illustrate operational realities without disclosing proprietary information.

Analytical rigor was maintained through a systematic framework that mapped segmentation, regional dynamics and strategic levers against development and commercial outcomes. Limitations of the study are acknowledged where proprietary data or emerging clinical outcomes remain confidential, and recommendations emphasize actions that can be implemented with standard due diligence. Overall, the methodology balances depth of technical insight with practical relevance for commercial decision-making.

A concise synthesis of strategic imperatives and practical takeaways to convert buccal delivery innovation into commercial and clinical success

In conclusion, buccal drug delivery systems occupy an increasingly important role within the pharmaceutical toolkit, offering distinct clinical and commercial advantages where rapid onset, avoidance of first-pass metabolism and outpatient-friendly administration are priorities. The interplay between polymer innovation, device engineering and regulatory strategy has broadened feasible therapeutic applications, while patient-centric design and digital adjuncts enhance real-world value. The sector is responding to external pressures such as trade policy and supply chain risk by accelerating supplier diversification and regional manufacturing alignment, which in turn influences program economics and go-to-market sequencing.

Decision-makers should focus on aligning formulation choices with clear clinical articulation of benefit, investing in manufacturability and regulatory readiness early, and leveraging partnerships to access specialized competencies. Regional nuance in regulatory and payer environments necessitates tailored market-entry strategies, and companies that demonstrate both technical excellence and operational resilience are best positioned to win. The recommendations presented herein provide a pragmatic blueprint to prioritize investments and accelerate commercialization while maintaining compliance and protecting quality.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancement in mucoadhesive nanoparticle formulations for enhanced buccal drug bioavailability
  • 5.2. Application of 3D printing technologies to customize buccal film dosage forms for personalized therapy
  • 5.3. Exploration of permeation enhancers to optimize drug absorption through buccal mucosa membranes
  • 5.4. Development of sustained-release buccal adhesive gels for chronic pain management therapies
  • 5.5. Use of wireless sensors in buccal patches for real-time monitoring of patient drug compliance
  • 5.6. Implementation of cyclic peptide-based carriers to improve stability of buccal vaccine delivery
  • 5.7. Regulatory challenges and harmonization efforts impacting novel buccal drug delivery approvals
  • 5.8. Growth in chronic disease management using transbuccal delivery of peptide and small molecule drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Buccal Drug Delivery Systems Market, by Product Type

  • 8.1. Films
    • 8.1.1. Cellulose Derivatives
      • 8.1.1.1. Hydroxypropyl Methylcellulose
      • 8.1.1.2. Microcrystalline Cellulose
    • 8.1.2. Natural Polymers
    • 8.1.3. Synthetic Polymers
  • 8.2. Gels
    • 8.2.1. Hydrogels
    • 8.2.2. Organogels
  • 8.3. Patches
    • 8.3.1. Adhesive Patches
    • 8.3.2. Matrix Patches
  • 8.4. Sprays
    • 8.4.1. Multi Actuation
    • 8.4.2. Single Actuation
  • 8.5. Tablets
    • 8.5.1. Chewable Tablets
    • 8.5.2. Lozenges
    • 8.5.3. Mucoadhesive Tablets

9. Buccal Drug Delivery Systems Market, by Drug Class

  • 9.1. Analgesics
    • 9.1.1. Buprenorphine
    • 9.1.2. Fentanyl
  • 9.2. Cardiovascular
    • 9.2.1. Nitroglycerin
  • 9.3. Central Nervous System
  • 9.4. Hormones
    • 9.4.1. Estradiol
    • 9.4.2. Testosterone

10. Buccal Drug Delivery Systems Market, by Application

  • 10.1. Cardiovascular Treatment
  • 10.2. Hormone Therapy
  • 10.3. Pain Management
  • 10.4. Psychiatry

11. Buccal Drug Delivery Systems Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals

12. Buccal Drug Delivery Systems Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Buccal Drug Delivery Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Buccal Drug Delivery Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Buccal Drug Delivery Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. Novartis AG
    • 16.3.3. Johnson & Johnson
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Bayer AG
    • 16.3.6. Teva Pharmaceutical Industries Ltd.
    • 16.3.7. Viatris Inc.
    • 16.3.8. Bausch Health Companies Inc.
    • 16.3.9. BioDelivery Sciences International, Inc.
    • 16.3.10. Roche Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BUCCAL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BUCCAL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BUCCAL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICROCRYSTALLINE CELLULOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC POLYMERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORGANOGELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ADHESIVE PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MATRIX PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MULTI ACTUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SINGLE ACTUATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEWABLE TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LOZENGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MUCOADHESIVE TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NITROGLYCERIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ESTRADIOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TESTOSTERONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PSYCHIATRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANALGESICS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY FILMS, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BUCCAL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CELLULOSE DERIVATIVES, 2018-2024